Cartesian Q1 net loss $39.2M ($1.46/sh) vs $17.7M; cash $120.4M; pipeline advances

Cartesian Therapeutics, Inc.

2026-Q1 EPS reported -$1.46 revenue$78,000

Net loss widened to $39.2M from $17.7M YoY; higher R&D spend on Phase 3 AURORA trial.
Cash, equivalents & restricted cash $120.4M as of March 31; raised $14.6M via ATM in Q1.
Phase 3 AURORA trial enrollment continues; Phase 2 TRITON in myositis initiated; HELIOS pediatric trial progress.
R&D expenses $19.5M (up 33% YoY) due to AURORA; G&A $7.1M (down 14% YoY).
Cash runway expected into mid-2027, supporting completion of Phase 3 AURORA trial.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001453687-26-000081
form_type: 8-K
ticker: RNAC
cik: 0001453687
company_name: Cartesian Therapeutics, Inc.
filed_at: 2026-04-30T23:59:59+00:00
discovered_at: 2026-05-14T18:02:32.306448+00:00
generated_at: 2026-05-15T00:40:03.812412+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001453687-26-000081
json_url: https://secwatch.observer/filing/0001453687-26-000081.json
markdown_url: https://secwatch.observer/filing/0001453687-26-000081.md
text_url: https://secwatch.observer/filing/0001453687-26-000081.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368726000081/0001453687-26-000081-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368726000081/rnac-20260430.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001453687-26-000081

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.